Document is current

Article History

Received: 11 December 2024

Accepted: 30 December 2024

First Online: 1 May 2025

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki (Japan Medical Association translation), the Act on the Protection of Personal Information, and the Ethical Guidelines for Medical and Health Research Involving Human Subjects.

: All enrolled patients received a full explanation of the contents of this clinical research and provided written consent to participate.

: Ippei Miyamoto declared no financial and non-financial disclosures. Shunshuke Kondo reported honoraria from ONO, AstraZeneca K.K, TAIHO, Daiichi Sankyo, Eisai, and Chugai; payment for expert testimony from Cmic, SHIONOGI & CO, and Sanofi K.K; participation on a Data Safety Monitoring Board or Advisory Board from Cmic Co and SHIONOGI & CO. Shigehisa Kitano reported support for this manuscript from Chugai; grants from Chugai, Eisai, Astellas, Takara Bio, Pfizer, Incyte, Takeda, Eli Lilly/LOXO, Merck KGaA, Ono, Boehringer Ingelheim, Daiichi Sankyo, MSD, Astra Zeneca, Abbvie, GSK, and Kyowa Kirin: consulting fees from Chugai, Astra Zeneca, GSK, ImmuniT Research, Astellas, Ono, Sumitomo Pharma, Rakuten Meidical, United Immunity, and Kyowa Kirin; honoraria from Chugai, Ono MSD, Boehringer Ingelheim, Eizai, Eli Lilly, Daiichi Sankyo, Takeda, Bristol-Myers Squibb, AstraZeneca, Pfizer, Taiho, GSK, Novartis, Astellas, and Merck KGaA. Jun Sato reported honoraria from Eisai, Chugai and Fuji Film. Yuki Katsuya reported support from Ono Pharma for attending meetings. Takahiro Kogawa reported consulting fees from Daiichi Sakyo and Astellas Pharma; honoraria from Daiichi Sakyo, Eisai, Ono, Astra Zeneca, Gilead Sciences, Taiho Pharma, Astellas Pharma, and Chugai; Payment for expert testimony from Astellas Pharma; support for attending meetings from Phyzer and Eisai; participation on a Data Safety Monitoring Board or Advisory Board from Daiichi Sakyo, Eisai, Ono, Astra Zeneca, Gilead sciences, Taiho, Oncotherapy Sciences; receipt of services from Daiichi Sakyo. Hidenori Mizugaki reported honoraria from Chugai, Daiichi Sankyo, AstraZeneca K.K, Takeda, and Merck. Hiroaki Tomita, Tatsuki Imaizumi and Chika Murakami reported employment and stocks owned at Chugai. Shunichiro Iwasawa and Takeshi Miyake reported employment at Chugai. Noboru Yamamoto reported grants from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Pharma, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, AstraZeneca, Cmic, InventisBio, Rakuten Medical, Amgen, and Bicycle Therapeutics; consulting fees received from Eisai, Takeda, Boehringer Ingelheim, Cmic, Chugai, MERCK, Healios, and Noile-Immune Biotech; honoraria as a speaker from Chugai, Daiichi-Sankyo, and Eisai.